Tuesday, March 19, 2013

Actavis Inc (NYSE: ACT)

Actavis, Inc., an integrated specialty pharmaceutical company, engages in developing, manufacturing, marketing, selling, and distributing generic, branded generic, brand, biosimilar, and over-the-counter pharmaceutical products worldwide. The company offers its products for various therapeutic categories, such as cardiovascular, dermatology, urology, women's health, oncology, pregnancy prevention, hormones and synthetic substitutes, anti-infective agents, central nervous system, pain management, depression, hypertension, attention-deficit/hyperactivity disorder, and smoking cessation.
It operates through three segments: Actavis Pharma, Actavis Specialty Brands, and Anda Distribution. The Actavis Pharma segment develops, manufactures, and sells generic pharmaceutical products, as well as distributes generic versions of third parties brand products. The Actavis Specialty Brands segment promotes and co-promotes Rapaflo, Gelnique, Crinone, Trelstar, Generess Fe, Androderm, Kadian, Crinone, AndroGel, INFeD, and sodium ferric gluconate branded products. The Anda Distribution segment distributes generic and selected brand pharmaceutical products, vaccines, injectables, and over-the-counter medicines to independent pharmacies, alternate care providers, pharmacy chains, and physicians offices. Actavis, Inc., sells its generic and brand pharmaceutical products primarily to drug wholesalers, retailers, and distributors; hospitals, clinics, mail order, and government agencies; and managed healthcare providers.
To analyze Actavis' stock for potential trading opportunities, please take a look at the 1-year chart of ACT (Actavis, Inc.) below with my added notations:
1-year chart of ACT (Actavis, Inc.) Back in October, November and December ACT hit resistance at $90 (blue). During the last week of December the stock experienced a false breakout (red) thru that resistance only to fall back below it the next day. Earlier this week ACT broke through $90 again. Is the 2nd time a charm for the stock?
The Tale of the Tape: ACT has broken through its $90 resistance, again. A long position could be entered on a pullback to $90 with a stop placed below that level, or a short trade could be placed on a break back below $90, if that should happen.

Please bookmark us

No comments:

Post a Comment